Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 9, 2026, 4:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 13,641 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: National Cancer Institute (NCI) Clear all
Completed Phase 1 Interventional

Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features

NCT01048892
View directory record Official record
Conditions
Adrenocortical Carcinoma, Gastrointestinal Carcinoid Tumor, Kidney Cancer, Neuroblastoma, Retinoblastoma, Sarcoma
Interventions
Seneca Valley virus-001, cyclophosphamide, laboratory biomarker analysis, pharmacological study
Biological · Drug · Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
3 Years to 21 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
18
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

AZD2281 and Cisplatin Plus Gemcitabine to Treat Solid Tumor Cancers

NCT00678132
View directory record Official record
Conditions
Neoplasms
Interventions
AZD 2281, Cisplatin, Gemcitabine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional

A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma

NCT00131898
View directory record Official record
Conditions
Sarcoma
Interventions
Surgical Resection, Intensity Modulated Radiation Therapy (IMRT)
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 23, 2008 · Synced Oct 9, 2026, 4:02 AM EDT
Active, not recruiting Phase 1 Interventional

Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy

NCT02432963
View directory record Official record
Conditions
Adult Solid Neoplasm, Bladder Carcinoma, Colon Carcinoma, Estrogen Receptor Negative, Head and Neck Squamous Cell Carcinoma, Hepatocellular Carcinoma, HER2/Neu Negative, Melanoma, Non-Small Cell Lung Carcinoma, Pancreatic Carcinoma, Progesterone Receptor Negative, Rectal Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Triple-Negative Breast Carcinoma, TP53 Gene Mutation, Unresectable Solid Neoplasm
Interventions
Laboratory Biomarker Analysis, Modified Vaccinia Virus Ankara Vaccine Expressing p53, Pembrolizumab
Other · Biological
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Jan 28, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Not listed Not applicable Interventional

Chest X-Ray or Chest CT Scan in Patients at High Risk of Developing Lung Cancer

NCT00006087
View directory record Official record
Conditions
Lung Cancer
Interventions
annual screening, bronchoscopic and lung imaging studies, comparison of screening methods, computed tomography, radiography, study of high risk factors
Procedure
Lead sponsor
Jewish Hospital and St. Mary's Healthcare
Other
Eligibility
40 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Feb 9, 2009 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer

NCT02184533
View directory record Official record
Conditions
Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer, Stage IV Prostate Cancer, Multiple Myeloma, Plasmacytoma
Interventions
sodium selenite, radiation therapy, laboratory biomarker analysis, pharmacological study, questionnaire administration
Drug · Radiation · Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 28, 2024 · Synced Oct 9, 2026, 4:02 AM EDT
Enrolling by invitation No phase listed Observational

Bone Marrow Grafting for Leukemia and Lymphoma

NCT00186147
View directory record Official record
Conditions
Leukemia, Lymphoma, Hematologic Diseases
Interventions
collection and storage of tissue samples for research
Procedure
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
9,999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1988 – 2069
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

Laparoscopic Staging in Patients With Ovarian, Fallopian Tube, or Other Primary Abdominal Cancers

NCT00002538
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
laparoscopic surgery
Procedure
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1993
U.S. locations
11
States / cities
Los Angeles, California • Palo Alto, California • Washington D.C., District of Columbia + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 3 Interventional Results available

Precision-exercise-prescription for Lung Cancer Patients Undergoing Surgery: The PEP Study

NCT03306992
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Secondary Lung Cancer
Interventions
Personalized Exercise Program
Behavioral
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
182 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer

NCT02066532
View directory record Official record
Conditions
Metastatic Breast Cancer, Breast Carcinoma, HER-2 Positive Breast Cancer
Interventions
Ruxolitinib, Trastuzumab
Drug
Lead sponsor
Dawn L. Hershman
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
4
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 24, 2023 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Title: Leveraging Technology to Address Health Outcomes of Cancer Survivors

NCT05499663
View directory record Official record
Conditions
Survivorship, Cancer, Symptoms and Signs
Interventions
POSTHOC app
Behavioral
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 6, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

NCT00089063
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma, Stage IIC Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IV Melanoma
Interventions
tyrosinase peptide, gp100 antigen, MART-1 antigen, incomplete Freund's adjuvant, Montanide ISA 51 VG, sargramostim, laboratory biomarker analysis
Biological · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2015 · Synced Oct 9, 2026, 4:02 AM EDT
Not listed No phase listed Observational

Blood Flow MRI for Monitoring Brain Tumors

NCT01538264
View directory record Official record
Conditions
Brain Tumors
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 26, 2024 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Human Laboratory Study of the Effects of Nicotine Product Claims on Appeal, Perceptions, and Use Behavior

NCT06192316
View directory record Official record
Conditions
Behavior, Risk
Interventions
3x3 between-subjects experimental exposure
Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
450 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional Results available

Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma

NCT03513952
View directory record Official record
Conditions
Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage III Bladder Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IV Bladder Cancer AJCC v8, Stage IV Renal Pelvis Cancer AJCC v8, Stage IV Ureter Cancer AJCC v8, Stage IV Urethral Cancer AJCC v8, Stage IVA Bladder Cancer AJCC v8, Stage IVB Bladder Cancer AJCC v8, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma
Interventions
Atezolizumab, Biopsy, Biospecimen Collection, Computed Tomography, Glycosylated Recombinant Human Interleukin-7, Laboratory Biomarker Analysis, Magnetic Resonance Imaging, Positron Emission Tomography and Computed Tomography Scan
Drug · Procedure · Biological + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
9
States / cities
Riverside, California • Tampa, Florida • Honolulu, Hawaii + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2024 · Synced Oct 9, 2026, 4:02 AM EDT
Not listed Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Recurrent Acute Lymphoblastic Leukemia or Non-Hodgkin's Lymphoma

NCT00004858
View directory record Official record
Conditions
Leukemia, Lymphoma
Interventions
B43-genistein immunoconjugate
Biological
Lead sponsor
Parker Hughes Cancer Center
Other
Eligibility
Up to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
3
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 2 Interventional Results available

Stereotactic Radiosurgery in Treating Patients With Brain Metastases

NCT00811655
View directory record Official record
Conditions
Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
therapeutic conventional surgery, stereotactic radiosurgery
Procedure · Radiation
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2013 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

S0007 - Combination Chemotherapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer

NCT00006248
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
cisplatin, fluorouracil, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
95
States / cities
Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 61 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2013 · Synced Oct 9, 2026, 4:02 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage With Ablation in Patients With Liver Tumors, the COVER-ALL Study

NCT04083378
View directory record Official record
Conditions
Malignant Liver Neoplasm
Interventions
Ablation Therapy, Image-Guided Therapy, Quality-of-Life Assessment, Questionnaire Administration
Procedure · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Driving Inclusivity, Validity, and Equity in Research Through Strategic Engagement (DIVERSE)

NCT06469307
View directory record Official record
Conditions
Blood Cancer, Leukemia
Interventions
DIVERSE Review Process
Other
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 2 Interventional Results available

Drosophila-generated CTL

NCT01271907
View directory record Official record
Conditions
Metastatic Cutaneous Melanoma
Interventions
fludarabine, cyclophosphamide, Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL, Aldesleukin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Oct 9, 2026, 4:02 AM EDT
Terminated Phase 3 Interventional Results available

Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

NCT00522392
View directory record Official record
Conditions
Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
bortezomib, lenalidomide, dexamethasone
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
275
States / cities
Scottsdale, Arizona • Fairfield, California • San Diego, California + 184 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2015 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 2 Interventional

Temozolomide in Treating Patients With Relapsed or Progressive Small Cell Lung Cancer

NCT00022711
View directory record Official record
Conditions
Lung Cancer
Interventions
temozolomide
Drug
Lead sponsor
Fox Chase Cancer Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
17
States / cities
Flemington, New Jersey • Lakewood, New Jersey • Millville, New Jersey + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2013 · Synced Oct 9, 2026, 4:02 AM EDT
Completed Phase 1 Interventional

Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed by Surgery

NCT01783171
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Recurrent Pancreatic Carcinoma, Stage III Pancreatic Cancer AJCC v6 and v7, Stage IV Pancreatic Cancer AJCC v6 and v7, Unresectable Pancreatic Carcinoma
Interventions
Akt Inhibitor MK2206, Dinaciclib, Laboratory Biomarker Analysis, Pharmacological Study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 22, 2017 · Synced Oct 9, 2026, 4:02 AM EDT